Date: 2026-04-06 Quarter: Q4 FY25 (Dec-2025) | Reported: 2026-02-25 Market cap: ~$1.0B | P/S: 0.6x | Revenue growth: +21.5% YoY
Here's how I'm thinking about Root after Q4. This is a company that just wrapped up its first full year of profitability — $40M net income, $192M free cash flow, $1.5B in revenue — and the market is valuing it at 0.6x sales. That's a number you typically see on companies bleeding cash with no path forward. Root is neither of those things.
But — and there's always a but — the growth trajectory is clearly decelerating, the accident-period loss ratio has gotten worse four quarters straight, and management just told you they're going to make less money in 2026 than they did in 2025. On purpose. So the question isn't "is Root a real company?" — it clearly is. The question is whether the investment in growth levers will reaccelerate the business or whether we're watching a company mature into a slow-growth insurer at a sub-500K PIF base.
I come down on the optimistic side, but not without reservations.
This is my first deep dive on ROOT, so I'm building beliefs from scratch. I've read Atlas's Q3 analysis (which called it 2/5 conviction) and Bear and Saul's Q4 updates to the rolling file. Let me set my priors based on Q3 context heading into Q4:
| Metric | Expected (pre-Q4) | Actual | Verdict |
|---|---|---|---|
| Revenue | $395-405M (+22-25% YoY) | $397.0M (+21.5%) | In-line — slightly lower on growth rate |
| QoQ revenue add | $8-15M (above Q3's paltry $4.9M) | +$9.2M (+2.4% QoQ) | In-line — modest rebound from Q3 stall |
| PIF | 475-490K (acceleration promised) | 481,869 (+3.3% QoQ, +16.2% YoY) | Met — >2x Q4 FY24 pace as promised |
| Net income | $5-15M (investment ramp + seasonality) | $5.3M | Low end — deliberate spend + loss ratio |
| Combined ratio | 98-101% (seasonal headwind) | GCR 98.8%, NCR 99.7% | Met — improvement from Q3's 101+, barely under 100 |
| APLR | 60-63% (seasonal winter headwind) | 62.8% | Concerning — 4th consecutive quarterly deterioration |
| Premium/policy | $1,540-1,580 | $1,531 (-3.3% YoY) | Miss — first YoY decline |
| IA channel | Continued strong | Tripled YoY new writings | Beat — strongest qualitative signal in the quarter |
| Q3 promises kept? | 5 promises outstanding | 5/5 kept | Perfect — management delivered on every commitment |
Key delta: Management kept every Q3 promise — PIF accelerated, marketing deployed, IA grew, loss ratio headwind was modest, rate adequacy maintained. That's a credibility-builder. But the headline profitability numbers are ugly on a YoY basis (net income -76%, op income -70%), and the APLR trend from 55.5% to 62.8% over four quarters is the number that keeps me up at night.
| Q1_FY25 | Q2_FY25 | Q3_FY25 | Q4_FY25 | FY25 | |
|---|---|---|---|---|---|
| Cal date | Mar-25 | Jun-25 | Sep-25 | Dec-25 | — |
| Revenue ($M) | 349.4 | 382.9 | 387.8 | 397.0 | 1,517.1 |
| YoY % | 37.1% | 32.4% | 26.9% | 21.5% | 29.0% |
| QoQ add ($M) | +22.7 | +33.5 | +4.9 | +9.2 | — |
| Gross margin | 41.2% | 39.1% | 38.3% | 38.1% | — |
| Op income ($M) | 23.7 | 27.3 | 0.3 | 10.5 | 61.8 |
| Op margin | 6.8% | 7.1% | 0.1% | 2.6% | ~4.1% |
| Net income ($M) | 18.4 | 22.0 | (5.4) | 5.3 | 40.0 |
| Adj EBITDA ($M) | 31.9 | 37.6 | 33.7 | 28.8 | 132.0 |
| PIF | 453,800 | 455,493 | 466,320 | 481,869 | — |
| Prem/policy ($) | 1,614 | 1,616 | 1,581 | 1,531 | — |
| APLR (gross) | 55.5% | 59.3% | 59.5% | 62.8% | ~59% |
| GCR | 94.0% | 94.3% | 101.3% | 98.8% | — |
| NCR | 95.6% | 95.2% | 102.1% | 99.7% | — |
| FCF ($M) | 26.8 | — | — | 65.9 | 192.4 |
| SBC ($M) | 6.4 | 8.4 | 11.6 | 13.7 | 40.1 |
This is the crux. Let me break it down.
What ROOT "Is" right now:
What ROOT "Could Be":
My read: ROOT is solidly in "is" territory for an insurtech. It's profitable, generating cash, at scale, with a credible technology moat. The "could be" elements are the growth levers — IA national rollout, Toyota/OEM ecosystem, geographic expansion — and they're real catalysts with real TAM behind them. But they're also unproven at scale.
Here's the thing that differentiates ROOT from a typical "could be" story stock: the growth levers don't need to work for the current business to be profitable. This isn't a pre-revenue biotech waiting for an FDA approval. It's a $1.5B insurer generating $192M in FCF. The growth levers are about whether it becomes a $5B insurer or a $2B insurer. Both outcomes are fine from a 0.6x P/S starting point.
Management credibility is high. 5/5 on Q3 promises. CFO returned to the call (she missed Q3 for a family medical matter — that's resolved). The proactive guide-down on 2026 NI is honest. They're not hiding behind "adjusted" numbers to mask the investment spend. I respect that.
The IA channel is the real deal. Tripled YoY new writings. Only appointed ~10% of agencies nationally. $100B+ TAM. Goosehead integration cut quote-to-bind time by 50%. This is the kind of distribution advantage that compounds — every new agency appointment is a permanent growth lever that produces recurring premium. This isn't a "one more quarter" hope. It's a distribution moat being built in real time.
The valuation is absurd. 0.6x P/S for a 21% grower with positive net income and $192M FCF. Even if growth decelerates to 10-15%, this is wildly cheap. The market is pricing in something catastrophic that I don't see in the data.
FCF is real and growing. $192M FY25 vs $184M FY24. Operating cash flow $207M. On a $1B market cap, that's a ~19% FCF yield. You can argue about the P/E being 45x on a $5.3M quarter, but the cash flow tells a different story.
Partnership model creates structural advantages. Carvana (4 years in, continuing optimization), Toyota (new, connected vehicle data), Hyundai (OEM data), Experian (financial services embedding), Goosehead (IA). These aren't just revenue channels — they're data moats. Every partnership gives Root more behavioral data, which improves pricing, which makes the next partnership easier to win.
APLR deterioration is not a rounding error. 55.5% -> 59.3% -> 59.5% -> 62.8% over four quarters. That's 7.3 points of deterioration in a year. Yes, Q4 has seasonal winter driving headwinds, and yes, 62.8% is still within the 60-65% long-term target range. But we're now at the upper end, and the trend is going the wrong way. If Q1 2026 doesn't show improvement (management guided it would), this becomes a serious red flag.
Premium per policy decline is concerning. $1,614 -> $1,616 -> $1,581 -> $1,531 through FY25. First YoY decline. Management frames this as "structural advantage" — better pricing models mean lower premiums for better risks, which should improve loss ratios over time. I buy the logic conceptually. But lower premiums per policy mean you need more policies to grow revenue. And if the APLR is going up while premiums go down, the margin math gets ugly fast. CEO declined to give a terminal figure, which tells me they don't know where it bottoms.
Revenue deceleration is persistent. Five consecutive quarters of YoY deceleration: 37.1% -> 32.4% -> 26.9% -> 21.5%. Some of this is just comps — Root went from $195M to $327M in Q4 FY23-FY24, so the base effect is massive. But the sequential adds tell the same story: Q2 added $33.5M, Q3 added $4.9M, Q4 added $9.2M. The engine isn't dead, but it's running on fewer cylinders than mid-2025.
2026 is an investment year with no specific targets. Lower net income. Higher loss ratio. More spending on distribution, technology, talent. No revenue guidance. No specific margin targets beyond "60-65% loss ratio." I understand the logic — invest when you have a capital cushion and the growth levers are in front of you. But it also means Q1 and Q2 2026 earnings could be soft, and the stock might get punished on a weak quarter when the investment thesis hasn't yet proven out.
SBC is accelerating. $6.4M -> $8.4M -> $11.6M -> $13.7M through FY25 quarters. That's $40.1M for the year, doubling from FY24. On a $40M net income base, SBC is 100% of GAAP net income. Not a deal-breaker, but worth watching if it continues accelerating.
Scuttlebutt concerns (from Atlas's Q3 analysis): NAIC complaint index 2-5x industry average. Glassdoor 2.7/5. These aren't numbers you can ignore. Customer complaints about claims delays and unexpected rate increases are retention killers. If the embedded distribution model lowers acquisition cost but high complaints drive churn, the effective CAC advantage shrinks. I'd want to see improvement here before getting fully comfortable.
I'm not a DCF guy. Here's how I think about it in relative terms:
| Metric | ROOT | Context |
|---|---|---|
| P/S (TTM) | 0.6x | Progressive trades at ~2.5x. Typical SaaS at 5-15x. |
| P/E (run-rate) | ~45x | Misleading — Q4 NI was depressed by investment spend. FY25 P/E ~25x. |
| PEG | 0.028x | Sub-0.5x is cheap. This is laughably cheap. |
| Rule of 40 | 38.1 | Below 40 (21.5% growth + 16.6% FCF margin). Close enough. |
| FCF yield | ~19% | $192M FCF / $1B market cap. This is equity-like return from cash flow alone. |
| EV/EBITDA | ~7-8x | On $132M Adj EBITDA. Very reasonable. |
The bull math is compelling: at 90% combined ratio (achievable if tech pricing holds), Root generates ~$170M underwriting profit plus investment income on float. At 20x that's $3.4B+ market cap. At 95% combined ratio it's $85M profit at 20x = $1.7B. Both are significant upside from $1B today.
The bear math: combined ratios stay ~100%, growth decelerates to low-teens, profitability is marginal. Stock stays range-bound at $1-1.5B. You still own a profitable insurer generating FCF, you just don't get the multiple expansion.
Even the bear case isn't a disaster at 0.6x P/S. The floor seems well-protected.
Here's where I net out. ROOT is a tryout-sized position for me — small enough that if the margin trends continue deteriorating, I'm not hurt badly, but large enough to participate if the growth levers start compounding.
Why not a starter? Three things need to prove out:
What would make it a starter?
What would make me cut it?
| Promise Made Q3_FY25 | Q4_FY25 Resolution | Grade |
|---|---|---|
| Q4 PIF acceleration | PIF 481,869 (+3.3% QoQ, >2x Q4 FY24 pace) | A |
| ~$5M incremental Q4 marketing | S&M +$8.4M YoY; R&D also stepped up | A |
| ~5 ppts seasonal loss ratio headwind | Net loss ratio 66.9% vs Q3 ~66%; modest headwind | A- (less than predicted) |
| IA growth / no slowdown | IA tripled new writings YoY | A+ |
| Broadly rate adequate | APLR 62.8% within 60-65% target (barely) | B+ (within range but trending wrong) |
Management grade: A- — All five promises kept. That's rare and it builds credibility. The only knock is the APLR trend, which is technically within guidance but deteriorating.
| Promise | Specificity | Testable In | My Confidence |
|---|---|---|---|
| Accelerating annual PIF growth 2026 | Directional | FY26 | Medium — IA and geographic levers support this |
| Q1 2026 elevated shopping, sequential PIF growth | Directional | Q1 FY26 | High — tax season is reliable seasonality |
| Q1 2026 loss ratio improvement vs Q4 | Directional | Q1 FY26 | Medium — seasonal, but APLR trend works against this |
| 2026 loss ratio within 60-65% | Range | FY26 | Medium-Low — we're at 62.8% and trending toward 65% |
| Lower full-year NI 2026 vs 2025 | Directional (down) | FY26 | High — they're telling you to expect it |
| All contiguous states by end 2027 | Specific | FY27 | Medium — regulatory approval is the gating factor |
Atlas rated ROOT 2/5 conviction after Q3, focused on the warrant-driven loss and combined ratios crossing 100%. Q4 partially addressed those concerns — combined ratios came back under 100%, all promises were kept, FY25 was profitable. But Atlas's concerns about revenue deceleration, telematics commoditization, and customer complaints remain valid.
Where I differ from Atlas: I give more weight to the IA channel tripling YoY with only 10% national penetration. That's a concrete, scalable growth lever — not a "could be." It's happening. And at 0.6x P/S, you're getting paid to be patient while it compounds.
Where I agree with Atlas: the APLR trend is genuinely concerning, the customer complaint data is a red flag, and the premium per policy decline needs to stabilize. This isn't a high-conviction name.
ROOT delivered a clean Q4 that resolved Q3's most pressing concerns: combined ratios back under 100%, management credibility confirmed with 5/5 promise delivery, PIF accelerated, and the IA channel continues to be the standout growth story. Full-year results were impressive — $1.5B revenue, $40M net income, $192M FCF, record PIF.
But the APLR trend (4 consecutive quarters of deterioration), premium per policy decline (first YoY drop), and persistent revenue deceleration (5 consecutive quarters) create enough uncertainty that I can't pound the table. The valuation at 0.6x P/S gives enormous margin of safety — I genuinely think the downside is well-protected — but the upside requires the growth levers (particularly IA and geographic expansion) to start inflecting visibly in 2026.
Tryout position. Let it earn its way up. Q1 2026 is the next checkpoint — if APLR improves, PIF continues accelerating, and sequential revenue adds recover above the Q3-Q4 pace, I'll consider promoting to a starter.
I could be wrong. Maybe the APLR trend is just seasonal noise and this thing reaccelerates into a multi-bagger from here. At 0.6x P/S, the risk-reward is pretty asymmetric. But I've been burned before by companies that keep promising "next quarter" will be the inflection. I'd rather be patient and let the data tell me when to get bigger.
As usual, thanks for reading.